In CML, treatment with ABL1 tyrosine kinase inhibitors (ABL1-TKI) and more recently inhibitors specifically targeting the ABL myristoyl pocket (STAMP) usually results in complete hematologic, deep, and durable molecular remissions conferring into excellent long-term overall survival (OS)3–5. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.